Surya Sinaga Immanuel

Dr. Surya Sinaga Immanuel

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Infection & Chemotherapy
Verified
Journal Article
Open access
IWI Gde Sastra Winata
I Gde Sastra Winata
LLLeonardo Leonardo
Leonardo Leonardo
RSRosalia Sylfiasari
Rosalia Sylfiasari
AEAngeline Ekafentie
Angeline Ekafentie
SISurya Sinaga Immanuel
Surya Sinaga Immanuel
FCFenyta Christyani
Fenyta Christyani
Winata IG, et al. Infect Chemother. 2025 Mar;57:e16. https://doi.org/10.3947/ic.2024.0120

1 January 2025 in Narra J
Verified
Journal Article
Open access
PDF file
SISurya Sinaga Immanuel
Surya Sinaga Immanuel
EYEric R. Yonatan
Eric R. Yonatan
GTGabriel Tandecxi
Gabriel Tandecxi
CAClifford P. Anthony
Clifford P. Anthony
JCJanice Z. Chan
Janice Z. Chan
VBVictor Bandana
Victor Bandana
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have proven to significantly reduce mortality and rehospitalization in heart failure with reduced ejection fraction (HFrEF). Supported by the 2023 European Society of Cardiology (ESC) guidelines and the safety, tolerability, and efficacy of rapid optimization of heart failure (STRONG-HF) trial, SGLT2i offer improved outcomes with a favorable safety profile, emphasizing their pivotal role in HFrEF management. The aim of this study was to evaluate early initiation with dapagliflozin and empagliflozin, focusing on their efficacy and safety in acute heart failure (AHF). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched seven databases for randomized controlled trials on SGLT2i in AHF (2019–2024). Outcomes included all-cause mortality, heart failure (HF)-related events, all-cause rehospitalization, length of hospital stay, diuretic response, serum electrolytes, and adverse events (AEs). The Cochrane Risk of Bias 2 tool was used. Data were analyzed using a random-effects model and presented as standardized mean differences and risk ratios with 95% confidence intervals. A subgroup analysis was conducted based on intervention. Nine studies encompassing 1,417 patients with a generally low risk of bias were included. Initiating SGLT2i within five days of admission significantly reduced in-hospital all-cause mortality risk by 42% and in-hospital worsening HF during rehospitalization by 39%. SGLT2i also significantly reduced serious AEs risk by 27%. No significant differences were found in other outcomes, including specific AEs (acute kidney injury, hepatic injury, symptomatic hypotension, hypoglycemia, urinary tract infections, and diabetic ketoacidosis). The analysis showed homogeneity, with no significant differences between SGLT2i. The study highlights that initiating SGLT2i within five days of admission significantly reduces all-cause mortality and worsening HF during rehospitalization, with a better safety profile than placebo.

1 January 2025 in Narra J
Verified
Journal Article
Open access
PDF file
IWI Gs. Winata
I Gs. Winata
SISurya Sinaga Immanuel
Surya Sinaga Immanuel
LLLeonardo Leonardo
Leonardo Leonardo
FRFransiskus X. Rinaldi
Fransiskus X. Rinaldi
GTGabriel Tandecxi
Gabriel Tandecxi
RWRichard Wijaya
Richard Wijaya
Beyond gynecological issues, women with endometriosis have a significant risk of cardiac outcomes. Despite this evidence, the extent and mechanisms of the association remain unclear. The aim of this study was to evaluate the association between endometriosis and the incidence of cerebro-cardiovascular disorders. Using preferred reporting items for systematic review and meta-analyses (PRISMA) guidelines, seven databases were searched as of October 14, 2024, for observational studies assessing the association between endometriosis and cerebro-cardiovascular disorders. The main outcome was major adverse cardiovascular and cerebrovascular event (MACCE) while the secondary outcomes included all-cause mortality, cerebrovascular accident (CVA), ischemic heart disease (IHD), myocardial infarction (MI), arrhythmia, and heart failure (HF). Bias was assessed with the risk of bias in non-randomized studies of exposures (ROBINS-E) tool. Odds ratios with 95% confidence interval (CI) were calculated using random-effects meta-analysis. Evidence certainty was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Robustness was assessed via sensitivity analyses and trial sequential analysis (TSA). Out of 3,141 studies, nine cohort studies encompassing 1,670,589 women (follow-up 7–28 years) were included. Endometriosis was associated with 24% higher odds of MACCE incidence (95%CI: 1.18–1.31, moderate certainty). In addition, having endometriosis increased the odds of CVA by 49% (95%CI: 1.20–1.85, high certainty), IHD by 64% (95%CI: 1.31–2.05, low certainty), MI by 53% (95%CI: 1.18–1.98, high certainty), arrhythmias by 24% (95%CI: 1.12–1.37, high certainty), and HF by 13% (95%CI: 1.03–1.25, high certainty). Endometriosis did not significantly associate with all-cause mortality. Sensitivity analyses and TSA reinforced all of these findings. In conclusion, endometriosis was significantly associated with increased odds of cerebro-cardiovascular disorders. Future research should clarify the underlying mechanisms and develop targeted prevention strategies.

27 November 2025 in Western Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
SISurya Sinaga Immanuel
Surya Sinaga Immanuel
JGJesslyn Ellenia Gotama
Jesslyn Ellenia Gotama
YSYeziel Sayogo
Yeziel Sayogo
ASAlvin Sunjaya
Alvin Sunjaya
GTGabriel Tandecxi
Gabriel Tandecxi
LSLeonardo Paskah Suciadi
Leonardo Paskah Suciadi
Introduction: Vagal maneuvers are first-line therapy for hemodynamically stable supraventricular tachycardia (SVT), yet the relative efficacy of the standard Valsalva Maneuver (SVM), modified Valsalva maneuver (MVM), carotid-sinus massage (CSM), and head-down deep breathing (HDDB) remains uncertain. We undertook a network meta-analysis (NMA) to define the optimal technique and explore age- and sex-related effect modification. Methods: We searched nine databases from inception to January 2025 for randomized controlled trials involving adults (≥ 18 years of age) with stable SVT treated with at least two of the four maneuvers. Primary outcomes were conversion to sinus rhythm after a single attempt after multiple attempts, and by the end of the trial. Secondary outcomes were the need for rescue intravenous (IV) antiarrhythmic drugs and maneuver-related adverse events (AEs). Bayesian random-effects NMA generated risk ratios (RR) with 95% credible intervals (CrIs); surface under the cumulative ranking curve (SUCRA) quantified hierarchy. We performed consistency, publication bias, and sensitivity analyses, and network meta-regression for mean age and female proportion. Results: Nineteen trials (n = 2,545) formed a connected network. The MVM was more than doubly effective for single-attempt conversion relative to the SVM (RR 2.71, 95% CrI, 2.26-3.31) and outperformed CSM (RR 6.57, 3.33-14.94) and HDDB (RR 1.30, 0.35-4.66); SUCRA = 88.7%. At the end of the trial, the MVM retained superiority over the SVM (RR 1.25, 1.03-1.56) and ranked the highest success rate (SUCRA = 81.3%). The MVM also reduced IV drug use vs the SVM (RR 0.64, 0.55-0.73) and CSM (RR 0.59, 0.37-0.90). No maneuver differed in multiple-attempt success or AEs. The HDDB technique was ranked highest in safety (SUCRA = 82.4%) but was supported only by a single, small study. Meta-regression showed no age or sex interaction. Inconsistency was minimal; the Egger test suggested small-study effects only for the IV-drug endpoint (P = .03). Conclusion: The MVM provides the greatest likelihood of rapid sinus rhythm restoration and the least need for rescue pharmacotherapy without increasing AEs, supporting its adoption as the default vagal strategy for SVT. Larger, standardized trials are warranted to confirm safety differentials and long-term outcomes.

17 June 2025 in Indian Heart Journal
Verified
Journal Article
Open access
SISurya Sinaga Immanuel
Surya Sinaga Immanuel
GTGabriel Tandecxi
Gabriel Tandecxi
FRFransiskus Xaverius Rinaldi
Fransiskus Xaverius Rinaldi
YSYeziel Sayogo
Yeziel Sayogo
ASAlvin Sunjaya
Alvin Sunjaya
VBVictor Bandana
Victor Bandana
Left atrial fibrosis (LAF) and left atrial volume index (LAVI), assessed via cardiac magnetic resonance (CMR), are emerging biomarkers for atrial cardiomyopathy and stroke risk. Their roles in the embolic stroke of undetermined source (ESUS) remain unclear. This study evaluates LAF and LAVI in ESUS and explores whether age modifies these outcomes. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO CRD42024615479), we searched eight databases (inception-October 2024) for studies evaluating LAF or LAVI via CMR in ESUS, compared to atrial fibrillation (AF) without stroke, cardioembolic stroke (CES), non-cardioembolic stroke (NCE), and healthy controls. We performed a Bayesian network meta-analysis to estimate mean differences (MD) with 95% credible intervals (CrI). Node-splitting tested consistency, and a meta-regression examined the effect of age. Ten observational studies with 1,285 patients (mean age 65.1 ± 12.1 years) were included, demonstrating a generally low risk of bias. ESUS patients had significantly higher LAF than healthy controls (MD 9.86%, 95% CrI 3.05%-16.62%). No significant LAF differences were found between ESUS and AF without stroke, CES, or NCE. LAVI did not differ significantly between ESUS and any comparator groups. Node-splitting indicated no inconsistencies. Age was not significantly associated with LAF or LAVI. ESUS patients show increased LAF compared to healthy individuals, suggesting a key role of LAF in ESUS pathogenesis. Nonetheless, the application of CMR-detected LAF as a prognostic biomarker requires prospective validation to confirm its clinical utility in predicting stroke recurrence.

22 October 2025 in Journal of Arrhythmia
Verified
Journal Article
Open access
HBHaikal Balweel
Haikal Balweel
SISurya Sinaga Immanuel
Surya Sinaga Immanuel
JBJordan Budiono
Jordan Budiono
FRFransiskus Xaverius Rinaldi
Fransiskus Xaverius Rinaldi
YSYeziel Sayogo
Yeziel Sayogo
AHAgus Harsoyo
Agus Harsoyo
Background: Atrial fibrillation (AF) is the most common arrhythmia and a major cause of ischemic stroke recurrence. Cryptogenic stroke (CS) survivors face a higher risk for newly diagnosed AF (NDAF), with subtle ECG markers—prolonged P‐wave duration (PWDur) and increased P‐wave dispersion (PWDis)—potentially serving as early indicators. We aimed to quantify baseline PWDur and PWDis differences between CS survivors with NDAF and those in sinus rhythm. Methods: Following PRISMA guidelines, we systematically searched nine databases through January 2025 for observational studies assessing baseline P‐wave indices in adult CS patients in sinus rhythm. Data extraction and risk of bias assessment using the ROBINS‐E tool were performed independently. Pooled mean differences (MD) with 95% confidence intervals (CI) were calculated using a random‐effects inverse‐variance model. Subgroup/sensitivity analyses were conducted by age groups, male proportion, region, follow‐up duration, percentage of comorbidities, AF definition and detection methods, and ECG parameter. Heterogeneity was assessed using Cochran's Q , τ 2 , and I 2 and interpreted using Cochrane thresholds; certainty was appraised with GRADE. Results: Ten studies, encompassing 1508 patients (mean age 66.72 ± 13.74 years; 55.7% male), met the inclusion criteria. Baseline PWDur was longer in the NDAF (MD 6.36 ms, 95% CI: 0.69–12.03, p = 0.03, I 2 = 73%, GRADE: moderate). Sensitivity analysis confirmed the robustness. PWDis remained non‐significant. Conclusion: Prolonged baseline PWDur may serve as a non‐invasive marker of atrial conduction abnormalities and a predictor of AF in CS survivors. Larger prospective studies are needed to validate its role in risk stratification and secondary stroke prevention. Trial Registration: PROSPERO: CRD42025646135